|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-2.94/-1.95
|
企業價值
514.62M
|
資產負債 |
每股賬面淨值
-1.79
|
現金流量 |
現金流量率
--
|
損益表 |
收益
69.56M
|
每股收益
1.48
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/05 22:41 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. |